FY2026 Earnings Estimate for COCP Issued By Noble Financial

Cocrystal Pharma, Inc. (NASDAQ:COCP – Free Report) – Equities researchers at Noble Financial decreased their FY2026 EPS estimates for shares of Cocrystal Pharma in a research report issued to clients and investors on Tuesday, November 17th. Noble Financial analyst R. Leboyer now anticipates that the company will post earnings of ($0.83) per share for the year, down from their previous estimate of ($0.61). The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($0.69) per share. Noble Financial also issued estimates for Cocrystal Pharma’s Q4 2026 earnings at ($0.21) EPS and FY2027 earnings at ($0.70) EPS.

Cocrystal Pharma (NASDAQ:COCP – Get Free Report) last announced its quarterly earnings results on Monday, November 16th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.02). The firm had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.10 million.

A number of other research firms have also weighed in on COCP. Weiss Ratings lowered Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. HC Wainwright reiterated a “buy” rating on shares of Cocrystal Pharma in a report on Friday, October 9th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Cocrystal Pharma has an average rating of “Hold”.

Check Out Our Latest Analysis on Cocrystal Pharma

Cocrystal Pharma Stock Down 3.3%

Shares of COCP stock opened at $0.98 on Thursday. The firm has a market cap of $18.82 million, a price-to-earnings ratio of -1.27 and a beta of 1.60. Cocrystal Pharma has a 52-week low of $0.76 and a 52-week high of $2.03. The company’s 50 day moving average is $1.07 and its 200 day moving average is $1.10.

About Cocrystal Pharma

(Get Free Report)

Cocrystal Pharma, Inc. is a biotechnology company focused on discovering and developing antiviral medicines. Its research targets viral proteins involved in replication, with the goal of developing treatments for infections including influenza, hepatitis C, norovirus and coronaviruses. The company uses structure-based drug discovery and computational methods to identify compounds that act on these viral targets. Its investigational programs have included candidates for influenza A and hepatitis C; these are research-stage medicines and are not approved treatments.

See Also

Earnings History and Estimates for Cocrystal Pharma (NASDAQ:COCP)

Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.